Loading
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.
Previous close
$5.54
+$0.02 · +0.36%
After-hours
$5.52
−$0.02 · -0.36%
Oct 7, 4:04 PM ET
Regular session · ET · Market data may be delayed.
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.
Day range
Current $5.54
52-week range
Current $5.54
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
25
Expensive
Sentiment
53
Mixed
Risk
90
Extreme Risk
Momentum
20
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.
Day range
Current $5.54
52-week range
Current $5.54
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | 267.38K USD | — | 147.75K USD | 59.41K USD |
| Gross profit | — | −267.38K USD | — | −147.75K USD | −59.41K USD |
| Research and development | 3.71M USD | 1.87M USD | 527.48K USD | 348.08K USD | 454.45K USD |
| Selling, general, and administrative | 5.91M USD | 3.8M USD | 1.34M USD | 836.83K USD | 778.99K USD |
| Operating expenses | 9.72M USD | 5.66M USD | 1.8M USD | 1.18M USD | 1.23M USD |
| Interest income | — | 77.61K USD | 100 USD | 98 USD | — |
| Depreciation and amortization | 287.96K USD | 267.38K USD | 196.94K USD | 147.75K USD | 59.41K USD |
| Operating income | −9.72M USD | −5.93M USD | −1.8M USD | −1.33M USD | −1.29M USD |
| Net income | −9.16M USD | −5.86M USD | −2.04M USD | −1.4M USD | −1.21M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
